Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Epizyme Inc (NQ: EPZM )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 11, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Epizyme Inc

< Previous 1 2 3 4 5 Next >
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
Recap: Epizyme Q2 Earnings
Shares of Epizyme (NASDAQ:EPZM) moved higher by 13.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 8.62% year... 
Via Benzinga
Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal
Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to... 
Via Talk Markets
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
68 Biggest Movers From Yesterday
Gainers Golden Nugget Online Gaming, Inc. (NASDAQ: GNOG) shares climbed 50.8% to close at $18.50 on Monday after the company and DraftKings announced they entered into a... 
Via Benzinga
Epizyme, inc (EPZM) Q2 2021 Earnings Call Transcript
EPZM earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Epizyme Is Getting Crushed Today
It's uncomfortable when a company delivers an earnings miss and announces a CEO's departure on the same day. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks That Hit 52-Week Lows On Monday
Before 10 a.m. ET Monday, 63 stocks made new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was PACCAR (NASDAQ:PCAR).... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 30.38% to $2.36 during Monday's pre-market session. The company's market cap stands at $61.9 million. The... 
Via Benzinga
Epizyme Announces CEO Succession
From Epizyme, Inc.
Via Business Wire
Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update
From Epizyme, Inc.
Via Business Wire
20 Stocks Moving in Monday's Pre-Market Session
Gainers Windtree Therapeutics, Inc. (NASDAQ: WINT) shares rose 55.8% to $2.82 in pre-market trading after dropping over 10% on Friday. The company recently reported a wider loss... 
Via Benzinga
Epizyme Stock Gains On Potential $310M Pact With HUTCHMED For Cancer-Focused Tazverik In Greater China
Epizyme Inc (NASDAQ: EPZM) and HUTCHMED (China) Limited (NASDAQ: HCM) have collaborated to research, develop, manufacture, and commercialize Tazverik (... 
Via Benzinga
Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Date of Second Quarter 2021 Financial Results
From Epizyme, Inc.
Via Business Wire
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
Why Epizyme Stock Is Falling This Week
The cancer drug developer's CFO will soon exit the company. 
Via The Motley Fool
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19 Product Safety
Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients
From Epizyme, Inc.
Via Business Wire
Epizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models
Epizyme Inc (NASDAQ: EPZM) has reported positive data from mouse studies for potential first-in-class therapy, EPZ-719, that targets the enzyme SETD2. The... 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
Epizyme to Participate in Jefferies Virtual Healthcare Conference
From Epizyme, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.